clinical trial · NCT06194201
A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis
Fujian Shengdi Pharmaceutical Co., Ltd.·phase2·recruiting·n = 40
Patients With Candidemia and/or Invasive CandidiasisHRS9432Caspofungin Acetate for Injection
brief summary
The Purpose of this study is to evaluate the efficacy and safety of intravenous HRS9432 in patients with candidemia and/or invasive candidiasis
started
Apr 27, 2024
primary completion
Jun 1, 2026
completion
Jun 1, 2026
last updated
Nov 18, 2024
official title
A Multi-centre, Randomized, Double-blind, Active Controlled, Parallel Groups, Phase II Study to Evaluate the Efficacy and Safety of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol